VanEck Gold Miners ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.04 (market cap $26.33B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: VanEck Gold Miners ETF is far larger — about 3.1× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GDX | HNGE | |
|---|---|---|
Market Cap | $26.33B | $8.47B |
Volume | 31,283,423 | 1,624,526 |
52-Week High | $115.84 | $105.14 |
52-Week Low | $68.28 | $31.17 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $8.09B |
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% over the past day, with a neutral technical signal and bearish moving averages. Key support is at $87, with resistance at $89. Financial ratios are unavailable, but recent news highlights institutional selling and comparisons between gold miners and physical gold ETFs. The fund's performance is influenced by gold prices and interest rate trends.
Outlook remains mixed amid gold price volatility and rising rates. Opportunities include potential catch-up if gold rallies, but risks involve further institutional outflows and macroeconomic pressure on metals. Investor sentiment is cautious, with technicals suggesting limited near-term momentum.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →